254 related articles for article (PubMed ID: 9076631)
1. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B.
Hwang SJ; Wu JC; Lee CN; Yen FS; Lu CL; Lin TP; Lee SD
J Gastroenterol Hepatol; 1997 Jan; 12(1):87-91. PubMed ID: 9076631
[TBL] [Abstract][Full Text] [Related]
2. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
4. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
Wada M
Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
[TBL] [Abstract][Full Text] [Related]
6. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
7. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study.
Sun Q; Zhang Q; Gu J; Sun WW; Wang P; Bai C; Xiao HP; Sha W
Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):908-17. PubMed ID: 26935778
[TBL] [Abstract][Full Text] [Related]
9. Early monitoring for detection of antituberculous drug-induced hepatotoxicity.
Lee CM; Lee SS; Lee JM; Cho HC; Kim WS; Kim HJ; Ha CY; Kim HJ; Kim TH; Jung WT; Lee OJ
Korean J Intern Med; 2016 Jan; 31(1):65-72. PubMed ID: 26767859
[TBL] [Abstract][Full Text] [Related]
10. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report.
Saigal S; Agarwal SR; Nandeesh HP; Sarin SK
J Gastroenterol Hepatol; 2001 Sep; 16(9):1028-32. PubMed ID: 11595068
[TBL] [Abstract][Full Text] [Related]
11. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
McNeill L; Allen M; Estrada C; Cook P
Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
[TBL] [Abstract][Full Text] [Related]
13. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP
Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870
[TBL] [Abstract][Full Text] [Related]
14. Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
Hagiwara E; Suido Y; Asaoka M; Katano T; Okuda R; Sekine A; Kitamura H; Baba T; Komatsu S; Ogura T
J Infect Chemother; 2019 Dec; 25(12):1026-1030. PubMed ID: 31229376
[TBL] [Abstract][Full Text] [Related]
15. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
16. Viral hepatitis prevalence in patients with active and latent tuberculosis.
Nooredinvand HA; Connell DW; Asgheddi M; Abdullah M; O'Donoghue M; Campbell L; Wickremasinghe MI; Lalvani A; Kon OM; Khan SA
World J Gastroenterol; 2015 Aug; 21(29):8920-6. PubMed ID: 26269682
[TBL] [Abstract][Full Text] [Related]
17. [Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence].
Moitinho E; Salmerón JM; Mas A; Bruguera M; Rodés J
Gastroenterol Hepatol; 1996 Nov; 19(9):448-51. PubMed ID: 8998667
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis.
Shin HJ; Lee HS; Kim YI; Lim SC; Jung JP; Ko YC; Kwon YS
Int J Tuberc Lung Dis; 2014 Mar; 18(3):347-51. PubMed ID: 24670574
[TBL] [Abstract][Full Text] [Related]
19. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers.
Wu JC; Lee SD; Yeh PF; Chan CY; Wang YJ; Huang YS; Tsai YT; Lee PY; Ting LP; Lo KJ
Gastroenterology; 1990 Feb; 98(2):502-4. PubMed ID: 2295408
[TBL] [Abstract][Full Text] [Related]
20. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
Chiu YM; Lai MS; Chan KA
PLoS One; 2018; 13(4):e0196210. PubMed ID: 29694398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
